374 related articles for article (PubMed ID: 19153118)
21. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
Jensen BV
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
[TBL] [Abstract][Full Text] [Related]
23. Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer.
Barac A; Isaacs C; M Shara N; Lynce F; Desale S; Haynes K; Potosky AL
J Cardiovasc Transl Res; 2020 Jun; 13(3):478-489. PubMed ID: 32458402
[TBL] [Abstract][Full Text] [Related]
24. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
25. Managing cardiotoxicity in anthracycline-treated breast cancers.
Ng R; Green MD
Expert Opin Drug Saf; 2007 May; 6(3):315-21. PubMed ID: 17480180
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
27. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
28. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
29. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy.
Nishi M; Wang PY; Hwang PM
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2648-2660. PubMed ID: 34587760
[TBL] [Abstract][Full Text] [Related]
31. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
Gramatyka M
Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
[TBL] [Abstract][Full Text] [Related]
32. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
33. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
34. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
36. Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance.
Lustberg MB; Reinbolt R; Addison D; Ruppert AS; Moore S; Carothers S; Suresh A; Das H; Berger M; Ramaswamy B; Wesolowski R; Binkley P; Raman SV; Shapiro CL
Circ Cardiovasc Imaging; 2019 May; 12(5):e008777. PubMed ID: 31060375
[No Abstract] [Full Text] [Related]
37. [An interpretation of expert panel consensus statement on prevention and treatment of anthracycline cardiotoxicity].
;
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):727-8. PubMed ID: 22339843
[No Abstract] [Full Text] [Related]
38. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
39. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
40. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review.
Simões R; Silva LM; Cruz ALVM; Fraga VG; de Paula Sabino A; Gomes KB
Biomed Pharmacother; 2018 Nov; 107():989-996. PubMed ID: 30257411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
